Abstract
Immune checkpoint blockade (ICB) has revolutionized the treatment of metastatic melanoma (MM). However, robust biomarkers of response and the identity of key antigenic targets remains lacking. We have previously demonstrated the importance of large peripheral CD8+ T cell clones in the ICB response; these clones being more cytotoxic and especially sensitive to ICB. However, identifying key groups of T cells based on their T cell receptor (TCR) usage has remained elusive.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
